Fusion protein · Antagonist of Interleukin-1 alpha (IL1A) and Interleukin-1 beta (IL1B) · developed by Kiniksa Pharmaceuticals
Rilonacept is a soluble decoy receptor that binds interleukin-1 alpha and interleukin-1 beta, preventing them from engaging cell surface IL-1 receptors, and also binds IL-1 receptor antagonist. It is used in cryopyrin-associated periodic syndromes, deficiency of IL-1 receptor antagonist, and recurrent pericarditis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Dec 16, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03737110 | Phase 3 | Recurrent Pericarditis | Completed | KNSA |
| NCT03980522 | Phase 2 | Recurrent Pericarditis | Completed | KNSA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Recurrent Pericarditis
Updated Oct 18, 2026. Something wrong or missing? Report it on the KNSA page.
See KNSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KNSA catalysts and pipeline →